Diagnostic value of gadobutrol versus gadopentetate dimeglumine in enhanced MRI of brain metastases
Purpose To compare gadobutrol and gadopentetate dimeglumine (Gd‐DTPA) contrast‐enhanced magnetic resonance imaging (MRI) at 3T for visualizing brain metastases. Materials and Methods The present randomized study included 60 consecutive patients with known or suspected brain metastases from systemic...
Gespeichert in:
Veröffentlicht in: | Journal of magnetic resonance imaging 2017-06, Vol.45 (6), p.1827-1834 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
To compare gadobutrol and gadopentetate dimeglumine (Gd‐DTPA) contrast‐enhanced magnetic resonance imaging (MRI) at 3T for visualizing brain metastases.
Materials and Methods
The present randomized study included 60 consecutive patients with known or suspected brain metastases from systemic malignancies. Two enhanced cerebral MR scans were performed in each patient within an interval of 2–5 days using different contrast agents (gadobutrol or Gd‐DTPA) at 3T. The dose of the contrast agents (0.1 mmol/kg Gd) was also identical. The axial T1 FLAIR images at 3, 7, and 10 minutes after the injection of the contrast agent were obtained for evaluation. Two experienced radiologists performed subjective evaluation of the image quality, made the choice of the optimal images, and performed an objective evaluation including: signal‐to‐noise ratio (SNR) of the brain metastases, contrast‐to‐noise ratio (CNR), contrast enhancement (CE), contrast‐to‐brain ratio (CBR), and contrast enhancement ratio (CER) of the brain metastases.
Results
Subjective evaluation showed that at 3, 7, and 10 minutes gadobutrol elicited higher scores (margin score: 3.56 ± 0.74 vs. 3.33 ± 0.93, 3.68 ± 0.57 vs. 3.45 ± 0.81, 3.58 ± 0.71 vs. 3.43 ± 0.76; interior score: 2.83 ± 0.42 vs. 2.63 ± 0.61, 2.86 ± 0.38 vs. 2.73 ± 0.52, 2.80 ± 0.42 vs. 2.69 ± 0.53; and overall score: 4.42 ± 0.98 vs. 4.09 ± 1.19, 4.57 ± 0.75 vs. 4.26 ± 1.05, 4.48 ± 0.83 vs. 4.21 ± 1.03, respectively) in displaying the details and overall lesions than Gd‐DTPA (repeated measures analysis of variance [ANOVA], margin score: P = 0.001, < 0.0001, 0.006; interior score: P < 0.0001, 0.004, 0.009; and overall score: P = 0.001, < 0.0001, < 0.0001, respectively). Subjective optimal image evaluation showed that the percentage of image assessed as “gadobutrol was better than Gd‐DTPA (41.2–44.1%)” was greater than that assessed as “Gd‐DTPA was better than gadobutrol (5.9–26.5%).” Objective evaluation showed that at 3, 7, and 10 minutes the SNR (214.17 ± 85.70 vs. 199.57 ± 85.08, 214.80 ± 86.03 vs. 199.19 ± 84.74, and 213.83 ± 82.46 vs. 193.68 ± 79.59, respectively), CNR (68.64 ± 50.18 vs. 57.88 ± 51.06, 75.42 ± 53.19 vs. 63.74 ± 53.91, and 77.13 ± 51.86 vs. 63.21 ± 51.71, respectively), CE (101.76 ± 63.31 vs. 87.61 ± 64.85, 99.85 ± 61.56 vs. 85.08 ± 64.98, and 100.33 ± 58.63 vs. 82.73 ± 61.73, respectively), CBR (0.48 ± 0.32 vs. 0.40 ± 0.33, 0.54 ± 0.34 vs. 0.46 ± 0.35, and 0.56 ± 0.34 vs. 0.47 ± 0.34, respectively), and CER (0.99 ± |
---|---|
ISSN: | 1053-1807 1522-2586 |
DOI: | 10.1002/jmri.25491 |